FDA Approves Takeda’s (TAK) Mimrylo As First Hepcidin-Mimicking Treatment For Rare Blood Cancer

FDA approved Protagonist Therapeutics' and Takeda's drug rusfertide (Mimrylo) for polycythemia vera. Mimrylo, a weekly injection, controls red blood cell overproduction. Takeda has not disclosed the price. Analysts forecast peak sales up to $2B. Protagonist's stock has nearly tripled in a year. Mimrylo is Takeda's second of three anticipated drug launches.

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax (via Sanofi and Takeda) for the 2026–2027 season, targeting the XFG variant. The approvals are based on clinical and real-world data, with Pfizer and BioNTech's vaccine set to ship immediately. Over five billion doses of their vaccine have been distributed globally.

The FDA approved Takeda Pharmaceutical's (TAK) Mimrylo for polycythemia vera, a rare blood disorder. Mimrylo is the first therapy mimicking hepcidin to regulate iron and red blood cell production. Takeda plans to share further trial findings and seek approvals outside the U.S. The approval does not impact its financial forecast for the fiscal year ending March 2027. TAK stock rose 2.53% in after-hours trading.

Takeda (TSE:4502/NYSE:TAK) received U.S. FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV). The approval was supported by Phase 3 VERIFY trial results, showing 76.9% of patients achieved clinical response. MIMRYLO is designed to regulate iron distribution and reduce red blood cell overproduction, aiming to maintain hematocrit control and reduce phlebotomy burden.

Novavax's partners, Sanofi and Takeda, have secured regulatory approvals for an updated Nuvaxovid vaccine targeting the SARS-CoV-2 XFG variant for the 2026-2027 season in the U.S., EU, and Japan. Novavax will earn royalties on sales and milestones tied to approvals. Sanofi is expanding marketing efforts in the U.S. and internationally, while Takeda leads in Japan, where Nuvaxovid was the second-most-used vaccine in 2025-2026.

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.